No Data
No Data
Morgan Stanley Maintains Nautilus Biotechnology(NAUT.US) With Hold Rating, Cuts Target Price to $3
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments
Nautilus Biotechnology's Earnings Call: Progress Amid Challenges
Guggenheim Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating, Cuts Target Price to $2.5
Nautilus Biotechnology Price Target Lowered to $2.50 From $4 at Guggenheim
Earnings Call Summary | Nautilus Biotechnology(NAUT.US) Q4 2024 Earnings Conference